The First Autoregulated Total Artificial Heart Implant in the United States

Schroder, Jacob N.; McCartney, Sharon L.; Jansen, Piet; Plichta, Ryan P.; Katz, Jason N.; Smadja, David; Dewan, Krish C.; Milano, Carmelo A.

doi:10.1016/j.atssr.2022.09.007

Cited by 2 publications

(2 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is currently approved for use for bridge to transplantation, and a trial for use as destination therapy is ongoing. Another TAH, designed to be less thrombogenic than the existing device and to mimic native ventricular function by adjusting contractility in response to preload, is undergoing testing in humans [15]. Because of the perennial shortage of donor organs, development of TAHs more suitable for permanent use is an area of active interest [14].…”

Section: Types Of Mechanical Circulatory Support Devices Indications ...mentioning

confidence: 99%

Kidney health and function with left ventricular assist devices

Garcia

Walther

2023

Current Opinion in Nephrology &Amp; Hypertension

View full text Add to dashboard Cite

Purpose of reviewMechanical circulatory support (MCS) is a group of evolving therapies used for indications ranging from temporary support during a cardiac procedure to permanent treatment of advanced heart failure. MCS is primarily used to support left ventricle function, in which case the devices are termed left ventricular assist devices (LVADs). Kidney dysfunction is common in patients requiring these devices, yet the impact of MCS itself on kidney health in many settings remains uncertain.Recent findingsKidney dysfunction can manifest in many different forms in patients requiring MCS. It can be because of preexisting systemic disorders, acute illness, procedural complications, device complications, and long-term LVAD support. After durable LVAD implantation, most persons have improvement in kidney function; however, individuals can have markedly different kidney outcomes, and novel phenotypes of kidney outcomes have been identified.SummaryMCS is a rapidly evolving field. Kidney health and function before, during, and after MCS is relevant to outcomes from an epidemiologic perspective, yet the pathophysiology underlying this is uncertain. Improved understanding of the relationship between MCS use and kidney health is important to improving patient outcomes.

show abstract

Section: Types Of Mechanical Circulatory Support Devices Indications ...mentioning

confidence: 99%

Kidney health and function with left ventricular assist devices

Garcia

Walther

2023

Current Opinion in Nephrology &Amp; Hypertension

View full text Add to dashboard Cite

show abstract

“…The patient, a 39-year old male with diabetes and ischemic cardiomyopathy, was successfully bridged to transplant after 5 months of support on the device and has made a full recovery. 39 In 2022, CARMAT received approvals from the French National Agency for Medicine and Health Product Safety ("ANSM") and the Patient Protection Committee (CPP Ile-de-France XI) to restart the EFICAS Clinical Study that will include 52 eligible patients in France. 40 BiVACOR TAH BiVACOR Inc. (Houston, TX) is a promising continuous flow magnetically powered titanium pump designed to be first durable alternative to heart transplantation.…”

Section: Current Technology Syncardia Tahmentioning

confidence: 99%

In Search of the Holy Grail of Artificial Hearts: Are We There Yet?

Volod,

Colon,

Arabía

2023

Semin Thromb Hemost

View full text Add to dashboard Cite

The total artificial heart (TAH) has a long and rich history, being the product of decades of innovation, hard work, and dedication. This review examines the history of the TAH, a device that has revolutionized the treatment of end-stage biventricular heart failure. It reviews the development of the device from early concepts to the current state-of-the-art device, the SynCardia TAH, which has been implanted in over 2,000 patients worldwide. The article also discusses the challenges and successes experienced by researchers, clinicians, and patients throughout the development of TAH devices. Our focus will also be on discussing the hemostatic alterations in patients implanted with TAH and anticoagulation strategies to decrease associated thromboembolic risks. The article concludes with a look at other novel TAH devices and the future of TAH as an increasingly viable treatment for end-stage heart failure.

show abstract

The First Autoregulated Total Artificial Heart Implant in the United States

Cited by 2 publications

References 5 publications

Kidney health and function with left ventricular assist devices

Kidney health and function with left ventricular assist devices

In Search of the Holy Grail of Artificial Hearts: Are We There Yet?

Contact Info

Product

Resources

About